Quanterix Corp (NASDAQ:QTRX) – Stock analysts at Leerink Swann issued their FY2017 EPS estimates for Quanterix in a research report issued to clients and investors on Tuesday. Leerink Swann analyst P. Souda expects that the company will post earnings of ($1.17) per share for the year. Leerink Swann has a “Outperform” rating and a $27.00 price target on the stock. Leerink Swann also issued estimates for Quanterix’s Q4 2017 earnings at ($0.29) EPS, Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.22) EPS, FY2018 earnings at ($0.90) EPS, Q1 2019 earnings at ($0.17) EPS, Q2 2019 earnings at ($0.10) EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.30) EPS and FY2020 earnings at $0.37 EPS.
Several other equities analysts have also weighed in on the stock. BTIG Research assumed coverage on shares of Quanterix in a research report on Tuesday. They set a “buy” rating and a $26.00 price objective on the stock. Cowen assumed coverage on shares of Quanterix in a research report on Tuesday. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Quanterix in a research report on Tuesday. They set an “overweight” rating on the stock.
Quanterix (QTRX) opened at $19.48 on Thursday. The firm has a market cap of $394.36 and a P/E ratio of -12.57. Quanterix has a 52-week low of $15.56 and a 52-week high of $23.70.
In other Quanterix news, insider E Kevin Hrusovsky acquired 34,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were purchased at an average price of $15.00 per share, with a total value of $510,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Walt acquired 200,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 500,000 shares of company stock worth $7,500,000.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.